Literature DB >> 22360554

Intracellular proton pumps as targets in chemotherapy: V-ATPases and cancer.

Agustin Hernandez1, Gloria Serrano-Bueno, Jose R Perez-Castineira, Aurelio Serrano.   

Abstract

Cancer cells show a metabolic shift that makes them overproduce protons; this has the potential to disturb the cellular acid-base homeostasis. However, these cells show cytoplasmic alkalinisation, increased acid extrusion and endosome-dependent drug resistance. Vacuolar type ATPases (V-ATPases), together with other transporters, are responsible to a great extent for these symptoms. These multi-subunit proton pumps are involved in the control of cytosolic pH and the generation of proton gradients (positive inside) across endocellular membrane systems like Golgi, endosomes or lysosomes. In addition, in tumours, they have been shown to play an important role in the acidification of the intercellular medium. This importance makes them an attractive target to control tumour cell proliferation. In the present review we present the major characteristics of this kind of proton pumps and we provide some recent insights on their in vivo regulation. Also, we review some of the consequences that V-ATPase inhibition carries for the tumour cell, such as cell cycle arrest or cell death, and provide a brief summary of the studies related to cancer made recently with commercially available inhibitors. In the light of recent knowledge on the regulation of this proton pump, some new approaches to impair V-ATPase function are also suggested.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22360554     DOI: 10.2174/138161212799504821

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  20 in total

1.  The constitutive protease release by primary human acute myeloid leukemia cells.

Authors:  Maria Honnemyr; Øystein Bruserud; Annette K Brenner
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-19       Impact factor: 4.553

Review 2.  Regulation of luminal acidification by the V-ATPase.

Authors:  Sylvie Breton; Dennis Brown
Journal:  Physiology (Bethesda)       Date:  2013-09

3.  Biological characterization of the hygrobafilomycin antibiotic JBIR-100 and bioinformatic insights into the hygrolide family of natural products.

Authors:  Evelyn M Molloy; Jonathan I Tietz; Patricia M Blair; Douglas A Mitchell
Journal:  Bioorg Med Chem       Date:  2016-05-14       Impact factor: 3.641

4.  A distinct inhibitory mechanism of the V-ATPase by Vibrio VopQ revealed by cryo-EM.

Authors:  Wei Peng; Amanda K Casey; Jessie Fernandez; Emily M Carpinone; Kelly A Servage; Zhe Chen; Yang Li; Diana R Tomchick; Vincent J Starai; Kim Orth
Journal:  Nat Struct Mol Biol       Date:  2020-05-18       Impact factor: 15.369

5.  Regulation of Notch signaling and endocytosis by the Lgl neoplastic tumor suppressor.

Authors:  Marta Portela; Linda M Parsons; Nicola A Grzeschik; Helena E Richardson
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 6.  Tumour acidosis: from the passenger to the driver's seat.

Authors:  Cyril Corbet; Olivier Feron
Journal:  Nat Rev Cancer       Date:  2017-09-15       Impact factor: 60.716

7.  Lgl reduces endosomal vesicle acidification and Notch signaling by promoting the interaction between Vap33 and the V-ATPase complex.

Authors:  Marta Portela; Liu Yang; Sayantanee Paul; Xia Li; Alexey Veraksa; Linda M Parsons; Helena E Richardson
Journal:  Sci Signal       Date:  2018-06-05       Impact factor: 8.192

8.  The V-ATPase accessory protein Atp6ap1b mediates dorsal forerunner cell proliferation and left-right asymmetry in zebrafish.

Authors:  Jason J Gokey; Agnik Dasgupta; Jeffrey D Amack
Journal:  Dev Biol       Date:  2015-08-05       Impact factor: 3.582

9.  Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.

Authors:  Kirsten Lindner; Christiane Borchardt; Maren Schöpp; Anja Bürgers; Christian Stock; Damian J Hussey; Jörg Haier; Richard Hummel
Journal:  J Exp Clin Cancer Res       Date:  2014-09-01

10.  Bafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expression.

Authors:  Xiaodong Lu; Lufang Chen; Yuanyuan Chen; Qixiang Shao; Wenxin Qin
Journal:  Exp Ther Med       Date:  2015-09-22       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.